Oncolytics Biotech Files 6-K Report

Ticker: ONCY · Form: 6-K · Filed: May 9, 2024 · CIK: 1129928

Oncolytics Biotech INC 6-K Filing Summary
FieldDetail
CompanyOncolytics Biotech INC (ONCY)
Form Type6-K
Filed DateMay 9, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: disclosure, foreign-private-issuer, sec-filing

Related Tickers: ONCY

TL;DR

ONCOLYTICS BIOTECH (ONCY) filed a 6-K, confirming its foreign private issuer status and Canadian base.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on May 9, 2024, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations sector. This filing is for the month of May 2024 and indicates they file annual reports under Form 20-F.

Why It Matters

This filing provides routine disclosure for foreign private issuers, informing investors about the company's reporting status and location.

Risk Assessment

Risk Level: low — This is a routine disclosure filing for a foreign private issuer and does not contain new material financial or operational information.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The Form 6-K is a report of a foreign private issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of May 2024.

Where is Oncolytics Biotech Inc. located?

Oncolytics Biotech Inc. is located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.

Does Oncolytics Biotech Inc. file annual reports under Form 20-F or 40-F?

The filing indicates that Oncolytics Biotech Inc. files annual reports under cover of Form 20-F.

What is the SIC code for Oncolytics Biotech Inc.?

The Standard Industrial Classification (SIC) code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.

When was this Form 6-K filed?

This Form 6-K was filed on May 9, 2024.

Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-05-09 12:11:18

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date May 9, 2024 Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing